Comprehensive Report on Tozuleristide (BLZ-100): An Investigational Agent for Fluorescence-Guided Surgery

I. Executive Summary

Tozuleristide, also known by its investigational code BLZ-100, is a novel, first-in-class, injectable imaging agent under development by the privately held biotechnology company Blaze Bioscience, Inc. It is classified as a biotech product, specifically a peptide-dye conjugate, designed to provide real-time, intraoperative visualization of malignant tissue. The agent's structure comprises two key components: a synthetic variant of chlorotoxin (CTX), a peptide derived from scorpion venom that provides tumor-targeting specificity, and indocyanine green (ICG), a near-infrared (NIR) fluorescent dye that allows for tissue illumination. This dual-component design forms the basis of the company's "Tumor Paint®" platform technology.

The mechanism of action relies on the CTX moiety's ability to selectively bind to a constellation of proteins often overexpressed in the tumor microenvironment, including matrix metalloproteinase-2 (MMP-2) and neuropilin-1 (NRP1). This targeted binding leads to the accumulation and retention of Tozuleristide within cancerous tissue. Upon excitation with a compatible NIR imaging system, the ICG component fluoresces, enabling surgeons to visually differentiate tumor margins from surrounding healthy tissue with high precision.

Clinical development has demonstrated a favorable safety and tolerability profile across multiple Phase 1 trials in adults with glioma, skin cancer, and sarcoma, as well as in pediatric patients with central nervous system (CNS) tumors. A maximum tolerated dose has not been identified, and adverse events have been minimal. Pharmacokinetic studies reveal a short serum half-life, yet prolonged tumor fluorescence, providing strong evidence of specific target engagement and retention.

The most advanced clinical program is the pivotal Phase 2/3 PNOC012 trial (NCT03579602), which has completed enrollment of 123 pediatric patients with CNS tumors. This trial evaluates Tozuleristide in conjunction with the proprietary Canvas™ Imaging System, an integrated device designed for high-sensitivity NIR detection. The agent has received both Orphan Drug Designation and Fast Track Designation from the U.S. Food and Drug Administration (FDA) for its application in pediatric CNS tumors, highlighting the significant unmet need in this population.

However, the program faces a notable regulatory challenge. In January 2024, the FDA issued a Pre-Notice of Noncompliance to Blaze Bioscience for failure to submit the results of the completed PNOC012 trial to ClinicalTrials.gov within the mandated timeframe. This data gap creates uncertainty and represents a material risk for the program's advancement.

Competitively, Tozuleristide is positioned to address key limitations of existing fluorescence-guided surgery agents, particularly the limited efficacy of 5-aminolevulinic acid (5-ALA) in low-grade and pediatric gliomas. By demonstrating fluorescence in these specific tumor types, Tozuleristide has a clear opportunity to establish a strong clinical niche. The future success of Tozuleristide will depend on the timely publication of its pivotal trial data, resolution of the outstanding FDA compliance issue, and a viable commercialization strategy for its integrated drug-device system.

II. Introduction: The Clinical Imperative for Enhanced Intraoperative Visualization

The Challenge of Achieving Gross Total Resection (GTR) in Surgical Oncology

In the field of surgical oncology, the extent of resection is one of the most significant modifiable prognostic factors for a wide range of solid tumors. Achieving a gross total resection (GTR), where all visible cancerous tissue is removed, is directly correlated with improved progression-free survival and overall survival, particularly in neuro-oncology for the treatment of gliomas.[1] However, the infiltrative nature of many cancers, which lack clear demarcation from surrounding healthy tissue, makes GTR a formidable challenge for surgeons.

The current standard of care for tumor resection relies heavily on preoperative imaging such as MRI, intraoperative visual cues under white light, and the surgeon's tactile feedback (palpation).[4] These methods have inherent limitations. Preoperative imaging loses accuracy due to "brain shift" once surgery commences, and visual inspection alone is often insufficient to detect microscopic residual disease at the tumor margins.[1] This reliance on subjective assessment contributes to a high rate of positive surgical margins, where cancer cells are left behind, a primary driver of local recurrence and treatment failure.[4]

Overview of Tozuleristide (BLZ-100) as a Novel, Targeted Imaging Agent

To address this critical unmet need, a new class of intraoperative imaging agents is emerging to enhance surgical precision. Tozuleristide (BLZ-100) is a first-in-class investigational agent at the forefront of this field. Developed by Blaze Bioscience, Tozuleristide is a tumor-targeting fluorescent agent designed to provide surgeons with real-time, high-resolution visualization of cancer cells during an operation.[6] Marketed under the "Tumor Paint" concept, the agent is engineered to selectively accumulate in malignant tissue, which then "glows" under near-infrared light, allowing for a clear distinction between tumor and healthy tissue.[7] This technology aims to transform surgical oncology by enabling more complete and safer resections, thereby improving patient outcomes.

Developer Profile: Blaze Bioscience

Tozuleristide is being developed by Blaze Bioscience, Inc., a privately held biotechnology company based in Seattle, Washington, that is singularly focused on improving the lives of cancer patients through its Tumor Paint® platform.[7] The company was founded in 2010 by Dr. Jim Olson, a pediatric neuro-oncologist at the Fred Hutchinson Cancer Research Center and Seattle Children's Hospital, and Heather Franklin, a seasoned biotechnology executive.[9] This foundation provides the company with deep scientific credibility and a clear clinical focus. Integral to the Tozuleristide program is the development of the Canvas™ Imaging System, a proprietary device created by Teal Light Surgical, Inc., a wholly-owned subsidiary of Blaze Bioscience, highlighting the company's integrated drug-device strategy.[9]

III. Scientific Foundation and Mechanism of Action

A Dual-Component Conjugate: Structure and Function

Tozuleristide is a biologic drug classified as a peptide-dye conjugate. Its innovative design comprises two distinct functional moieties covalently linked to form a single agent capable of both targeting and illuminating cancer cells.[6]

The Targeting Moiety: Chlorotoxin (CTX)

The tumor-targeting capability of Tozuleristide is conferred by its peptide component, a synthetic variant of chlorotoxin (CTX).[16] Natural CTX is a 36-amino acid peptide neurotoxin isolated from the venom of the Israeli deathstalker scorpion,

Leiurus quinquestriatus.[6] Decades of research have established that CTX possesses a remarkable and inherent ability to selectively bind to a wide array of cancer cells, particularly those of neuroectodermal origin, such as gliomas, sarcomas, and melanomas, while showing minimal affinity for non-cancerous cells.[6] This tumor-specific binding is the cornerstone of the "Tumor Paint" platform, guiding the fluorescent payload directly to the site of malignancy.

The Imaging Moiety: Indocyanine Green (ICG)

The visualization component of Tozuleristide is indocyanine green (ICG), a well-characterized fluorescent dye.[6] ICG is excited by and emits light in the near-infrared (NIR) spectrum (approximately 700–850 nm).[1] The use of NIR light for in vivo imaging offers several distinct advantages over visible-light fluorophores like 5-ALA. NIR light experiences significantly less absorption and scattering by biological tissues, such as blood and water, allowing for deeper tissue penetration and a much lower background signal from endogenous autofluorescence.[1] This results in a superior signal-to-background ratio, which is critical for clearly delineating tumor margins, especially in deep-seated or highly vascularized tissues like the brain.

Elucidating the Cellular Binding Targets: A Critical Review of the Evidence

While the tumor-targeting ability of CTX is empirically established, its precise molecular binding mechanism has been a subject of scientific investigation and debate, with several proteins proposed as potential targets.

The Role of Matrix Metalloproteinase-2 (MMP-2)

Early research suggested that the tumor selectivity of CTX was due to its interaction with matrix metalloproteinase-2 (MMP-2), a zinc-dependent endopeptidase.[18] MMP-2 is frequently overexpressed in the tumor microenvironment of many cancers, including glioma, and plays a crucial role in degrading the extracellular matrix, which facilitates tumor invasion and metastasis.[23] The hypothesis was that CTX binds to MMP-2, possibly as part of a larger membrane-associated complex that includes other proteins like MMP-14 and αvβ3 integrin, thereby anchoring the imaging agent to the tumor cell surface.[18] Some reports even claimed that CTX binding inhibited MMP-2 activity, suggesting a potential therapeutic effect in addition to its diagnostic function.[18]

Investigating Annexin A2 (ANX2) and Neuropilin-1 (NRP1)

The MMP-2 binding hypothesis was subsequently challenged. A follow-up study using a pull-down assay failed to detect a direct and specific interaction between labeled CTX and recombinant MMP-2, casting doubt on its role as the primary receptor.[18] This ambiguity prompted further investigation, leading to the proposal of annexin A2 (ANX2), a calcium-dependent phospholipid-binding protein, as an alternative binding partner.[18]

More recently, another research group identified neuropilin-1 (NRP1) as a novel CTX target.[18] NRP1 is an endocytic receptor found on tumor and endothelial cells that is involved in angiogenesis and tumor progression. Subsequent biochemical studies have confirmed a strong interaction between CTX and both MMP-2 and NRP1, while failing to confirm binding to ANX2.[18]

Synthesis of Current Understanding

The collective body of evidence suggests that the tumor-targeting mechanism of CTX is not mediated by a single, exclusive receptor but is likely a multifactorial process. The ability of CTX to bind to a range of different proteins, such as MMP-2 and NRP1, which are commonly upregulated in the pathological microenvironment of diverse tumors, may explain its broad applicability across different cancer types.[18] This promiscuous yet tumor-selective binding profile may be the key to its function as a pan-tumor imaging agent. While this molecular ambiguity could present a challenge from a narrow regulatory perspective, it appears to be a functional strength, allowing Tozuleristide to effectively "paint" a variety of solid tumors.

The development of Tozuleristide as the first product from the "Tumor Paint®" platform signifies a broader strategic approach by Blaze Bioscience.[9] This platform is modular, consisting of a targeting peptide and a functional payload. This framework allows for future innovation by potentially swapping either component. For instance, different peptides could be used to target other cellular markers, or the ICG payload could be replaced with a therapeutic agent, transforming the platform from a diagnostic to a therapeutic tool. Tozuleristide thus serves as a critical proof-of-concept for this versatile technology.

IV. Preclinical and Clinical Development Program

The clinical development of Tozuleristide has been systematic, progressing from foundational safety studies in accessible tumors to pivotal trials in its primary target indication of pediatric CNS tumors. The program has consistently demonstrated a favorable safety profile and promising imaging capabilities.

Table 1: Summary of Key Tozuleristide Clinical Trials
NCT Number
NCT02097875
NCT02234297
NCT02464332
NCT03579602
NCT04743310
NCT05316688

Early Human Studies: Safety, Tolerability, and Pharmacokinetics

The first-in-human trial of Tozuleristide (NCT02097875) was conducted in 21 adult patients with known or suspected skin cancers, including basal cell carcinoma and melanoma.[8] This population was selected for its accessibility, allowing for non-invasive imaging to assess pharmacodynamics. The study established a strong foundational safety profile. Tozuleristide was well-tolerated at intravenous doses up to 18 mg, and a maximum tolerated dose (MTD) was not identified. There were no serious adverse events, deaths, or discontinuations due to adverse events. The only treatment-related adverse events reported in more than one patient were mild headache and nausea.[8] Critically, the study also provided the first human proof-of-concept for imaging, with positive fluorescence observed in 4 of 5 basal cell carcinomas and 4 of 4 melanomas at intermediate dose levels.[8]

Pharmacokinetic (PK) analyses from these early Phase 1 studies in both adult and pediatric populations revealed a consistent and important characteristic of the drug.[28] Tozuleristide exhibits a very short serum half-life (t1/2) of approximately 30 minutes. However, tumor-specific fluorescence has been observed from as early as 3-4 hours to as late as 27-48 hours post-administration.[28] This disconnect between the drug's rapid clearance from circulation and its prolonged retention in malignant tissue is a key finding. It strongly suggests that Tozuleristide is not merely passively accumulating due to vascular leakiness but is actively binding to and being retained by specific targets within the tumor, providing robust validation for its targeted mechanism of action.

Application in Neurosurgery: Glioma and CNS Tumors

Building on the initial safety data, the clinical program advanced into neuro-oncology. A Phase 1 dose-escalation study in 17 adults with newly diagnosed or recurrent glioma (NCT02234297) further confirmed the agent's safety at doses up to 30 mg.[11] This trial demonstrated that Tozuleristide could effectively illuminate both high-grade and low-grade gliomas, with the fluorescence intensity in high-grade tumors increasing in a dose-dependent manner.[28]

The program's most significant undertaking is the pivotal Phase 2/3 PNOC012 trial (NCT03579602). This randomized, blinded study enrolled 123 pediatric and young adult patients (ages 1 month to 30 years) with CNS tumors.[9] The trial was designed to rigorously evaluate the efficacy of Tozuleristide and the Canvas™ Imaging System compared to standard of care surgery without fluorescence guidance. The primary endpoints were designed to measure the sensitivity and specificity of fluorescence in identifying tumor tissue in surgically equivocal regions, while secondary endpoints included the extent of resection (EOR) and safety.[31] Blaze Bioscience announced the completion of enrollment for this pivotal trial in November 2022, a major milestone for the program.[9] The results of this study are highly anticipated and will be critical for any future regulatory submissions.

Investigation in Sarcoma (NCT02464332)

According to the DrugBank database, Tozuleristide was investigated in a Phase 1 safety study involving adult subjects with sarcoma undergoing surgery (NCT02464332).[30] However, a comprehensive search of published literature and conference proceedings did not yield any results, abstracts, or presentations related to this specific trial.[8] This absence of data represents a notable gap in the public understanding of Tozuleristide's development history. This could be attributable to several factors, including the possibility of neutral or unfavorable results, a strategic decision by the company to deprioritize the sarcoma indication in favor of the more advanced CNS tumor program, or simply a delay in publication. For potential investors or partners, this data gap is a point that requires clarification.

Exploration in Other Solid Tumors

Beyond the formally registered trials, Tozuleristide has demonstrated preclinical or early clinical proof-of-concept in a range of other solid tumors, including breast cancer.[7] The company has also indicated potential applications in prostate, head and neck, and colorectal cancers, suggesting a broad market potential for the Tumor Paint® platform technology.[7]

V. The Canvas™ Imaging System: An Integrated Technology

Device Overview and Role in NIR Fluorescence Detection

The clinical utility of Tozuleristide is dependent on a specialized imaging device capable of detecting its NIR signal. To this end, Blaze Bioscience's wholly-owned subsidiary, Teal Light Surgical, Inc., developed the Canvas™ Imaging System.[9] The Canvas system is an investigational medical device engineered to provide high-sensitivity detection of NIR light. A key design feature is its ability to function effectively under the ambient light conditions of a standard operating room, which represents a significant advantage in usability and workflow integration for surgeons.[9] The initial version of the device is adapted for seamless integration with surgical microscopes, the primary visualization tool in neurosurgery.[12]

Synergy with Tozuleristide

Tozuleristide and the Canvas system are not standalone products but are being developed and tested as a cohesive, integrated drug-device combination.[9] The success of the imaging agent is inextricably linked to the performance of the imaging system. The high sensitivity of the Canvas system is required to detect the specific, and potentially low, levels of fluorescence generated by a targeted agent like Tozuleristide, as opposed to the brighter, non-specific signals from passive dyes. This synergy was a central component of the pivotal PNOC012 trial design, which assessed the efficacy of the combined system.[31]

This integrated approach presents both challenges and strategic advantages. The development pathway for a drug-device combination is inherently more complex, time-consuming, and costly than for a drug alone, as it requires navigating regulatory pathways for both components. However, should this system achieve regulatory approval, it would establish a formidable competitive moat. A competitor would need to develop not only a biosimilar imaging agent but also a compatible, high-performance imaging system to rival the Blaze platform. By co-developing and optimizing the device specifically for Tozuleristide, Blaze has created a proprietary ecosystem that would be difficult for others to replicate, thus protecting its market position.

VI. Regulatory and Competitive Landscape

Tozuleristide is entering a dynamic field of fluorescence-guided surgery (FGS) with established players and distinct clinical needs. Its regulatory pathway has been facilitated by key FDA designations, but is also marked by a recent compliance issue.

Table 2: Comparative Analysis of Intraoperative Fluorescent Agents in Glioma Surgery
Agent
Tozuleristide (BLZ-100)
5-Aminolevulinic Acid (5-ALA)
Fluorescein Sodium
Indocyanine Green (ICG)

FDA Designations

Blaze Bioscience has successfully secured two important designations from the U.S. FDA that facilitate and expedite the development of Tozuleristide.

• Orphan Drug Designation (ODD): Tozuleristide was granted ODD for its use as a "Diagnostic for the management of malignant brain tumors".[45] This designation is granted to therapies addressing rare diseases or conditions affecting fewer than 200,000 people in the U.S. and provides incentives such as tax credits for clinical trials, exemption from user fees, and the potential for seven years of market exclusivity upon approval.
• Fast Track Designation: In April 2020, the FDA granted Fast Track designation to the Tozuleristide program for pediatric CNS tumors.[14] This designation is intended to facilitate the development and expedite the review of drugs that treat serious conditions and fill an unmet medical need, allowing for more frequent meetings with the FDA and eligibility for accelerated approval and priority review.

Regulatory Correspondence: The FDA Letter on NCT03579602

A significant event in the regulatory history of Tozuleristide occurred on January 29, 2024, when the FDA's Center for Drug Evaluation and Research (CDER) issued a "Pre-Notice of Noncompliance" letter to Blaze Bioscience.[50] The letter explicitly states that the company appears to have failed to submit the required results information for the pivotal PNOC012 trial (NCT03579602) to the ClinicalTrials.gov data bank within the one-year statutory deadline following the trial's primary completion date.

The letter serves as a formal warning, requesting that Blaze Bioscience review its records and submit the required information promptly. It outlines the potential consequences of continued non-compliance, which include a formal Notice of Noncompliance and the potential for civil monetary penalties of up to $10,000 per day until the violation is corrected.[50]

For a private, clinical-stage company like Blaze Bioscience, this public letter represents a material risk. Beyond the potential financial penalties, it raises questions regarding the company's operational and regulatory discipline. For potential investors or pharmaceutical partners conducting due diligence, such a finding can be a significant red flag, creating uncertainty about the reasons for the delay in data disclosure. The timely resolution of this issue and the transparent publication of the pivotal trial data are critical for the program's continued progress and for maintaining credibility with regulatory bodies and the investment community.

The competitive positioning of Tozuleristide appears most robust in the areas where current standards are weakest. The literature consistently demonstrates that 5-ALA, the current standard for FGS in gliomas, has a very low rate of visible fluorescence in low-grade gliomas (LGGs), with one systematic review reporting a positivity rate of only 7.3%.[40] In contrast, Phase 1 data for Tozuleristide have shown detectable fluorescence in LGGs.[28] This capability positions Tozuleristide to fill a significant clinical gap. This is particularly relevant in the pediatric population, where LGGs are more common and for which the agent has received Fast Track designation.[39] This suggests a clear initial market strategy: targeting patient populations where it can offer a distinct advantage over the established standard of care, rather than competing directly with 5-ALA in its strongest indication of high-grade adult gliomas.

VII. Strategic Analysis and Future Outlook

Consolidated Strengths, Weaknesses, Opportunities, and Threats (SWOT) Analysis

• Strengths:
• Novel, Targeted Mechanism: The peptide-dye conjugate platform provides tumor-specific binding, a key differentiator from passive dyes.[6]
• Favorable Safety Profile: Multiple Phase 1 trials have shown Tozuleristide to be well-tolerated with minimal adverse events.[8]
• Broad Applicability: Demonstrated fluorescence across multiple tumor types (glioma, skin, sarcoma, breast) suggests pan-tumor potential.[9]
• Integrated Imaging System: The co-developed Canvas system creates a proprietary, high-performance ecosystem, raising the barrier to entry for competitors.[9]
• Weaknesses:
• Ambiguous Molecular Target: The lack of a single, definitively confirmed binding partner for CTX could be a point of scientific and regulatory scrutiny.[18]
• Data Gap in Sarcoma: The absence of published results from the NCT02464332 sarcoma trial creates uncertainty about its efficacy in that indication.[30]
• Drug-Device Complexity: The requirement for dual regulatory approval for both the drug and the device increases development complexity and cost.[9]
• Opportunities:
• Unmet Need in LGG and Pediatrics: Tozuleristide's ability to illuminate low-grade and pediatric CNS tumors addresses a major limitation of the current standard, 5-ALA.[40]
• Platform Technology Expansion: The "Tumor Paint" concept allows for the development of future agents with different targeting peptides or therapeutic payloads.[9]
• Improved Surgical Outcomes: If proven to increase GTR rates, Tozuleristide could become a new standard of care, improving patient survival and quality of life.
• Threats:
• FDA Regulatory Scrutiny: The Pre-Notice of Noncompliance letter for delayed data submission is a significant regulatory risk that could impact future interactions and partnerships.[50]
• Competition: While it has a niche, it will still compete with established FGS agents and other emerging imaging technologies.[40]
• Commercialization Hurdles: Establishing reimbursement and market access for a novel drug-device combination can be challenging.

Key Unanswered Questions and Development Hurdles

The future trajectory of Tozuleristide hinges on the resolution of several critical questions:

1. What are the final efficacy and safety results from the pivotal PNOC012 trial? The public release of this data is the single most important near-term catalyst for the program.
2. What were the findings of the NCT02464332 sarcoma study? Clarification on why these results were never published is necessary to fully assess the agent's potential breadth of application.
3. How will Blaze Bioscience address the FDA's non-compliance letter? The company's response and the subsequent FDA action will be a key indicator of its regulatory standing and operational capabilities.
4. What is the commercialization strategy? The company needs to articulate a clear plan for pricing, reimbursement, and market adoption for the integrated Tozuleristide and Canvas system.

Recommendations for Future Research and Clinical Strategy

To maximize the potential of the Tozuleristide program, the following strategic steps are recommended:

1. Prioritize Regulatory Compliance and Transparency: Immediately address the FDA's concerns by submitting the complete results of the PNOC012 trial to ClinicalTrials.gov and preparing the data for peer-reviewed publication. This is essential to restore confidence and clear the path for future regulatory submissions.
2. Focus on the Core Clinical Niche: Double down on the development and regulatory strategy for pediatric CNS tumors and low-grade gliomas, where Tozuleristide holds the clearest competitive advantage over 5-ALA.
3. Conduct Comparative Effectiveness Research: Once approved, or in a future trial, conduct head-to-head studies directly comparing Tozuleristide/Canvas with 5-ALA in LGG to generate definitive evidence of clinical superiority, which would be crucial for market adoption and reimbursement negotiations.
4. Further Elucidate the Mechanism of Action: Continue research into the binding targets of CTX. Identifying predictive biomarkers (e.g., high expression of NRP1 or MMP-2) could allow for better patient selection and potentially lead to companion diagnostic development, further strengthening the platform's value proposition.

VIII. References

[15] Synapse. (n.d.).

Tozuleristide - Drug Targets, Indications, Patents.

6 National Cancer Institute. (n.d.).

NCI Drug Dictionary: Tozuleristide.

52 AdisInsight. (2025, April 21).

Tozuleristide - Blaze Bioscience.

7 Synapse. (n.d.).

What is Tozuleristide used for?.

8 Yamada, M., Miller, D. M., Lowe, M., Rowe, C., Wood, D., Soyer, H. P., Byrnes-Blake, K., Parrish-Novak, J., Ishak, L., Olson, J. M., Brandt, G., Griffin, P., Spelman, L., & Prow, T. W. (2021). A first-in-human study of BLZ-100 (tozuleristide) demonstrates tolerability and safety in skin cancer patients.

Contemporary Clinical Trials Communications, 23, 100830.

9 Business Wire. (2022, November 2).

Blaze Bioscience Announces Enrollment is Complete on its Pivotal Phase 2/3 Trial of tozuleristide and the CanvasTM Imaging System in Pediatric Central Nervous System Tumors.

36 Blaze Bioscience. (n.d.).

Press Releases.

18 Szabo, I., Bock, I., Juhasz, T., Hollo, K., Gonczi, M., Krizbai, I. A., & Deli, M. A. (2023). Chlorotoxin binds to both matrix metalloproteinase 2 and neuropilin 1.

Journal of Biological Chemistry, 299(9), 105151.

53 Zhao, H., et al. (2024). Fluorescence-Guided Surgery for Gliomas: An Overview of Current Applications and Future Perspectives.

Molecules, 29(12), 2019.

20 O'Connor, E., et al. (2021). Timing of Fluorophore Administration in Fluorescence-Guided Surgery for Glioma Patients.

Frontiers in Neurology, 12, 682151.

10 Oregon State University Libraries. (n.d.).

A first-in-human study of BLZ-100 (tozuleristide) demonstrates tolerability and safety in skin cancer patients.

11 BioSpace. (2019, May 9).

Blaze Bioscience Announces the Publication of Phase 1 Clinical Trial Results for Tumor Paint: BLZ-100 (tozuleristide) in Adults with Glioma.

33 Miller, D. M., Leary, S., Lee, A., Patil, C., Walker, D., Ishak, L., Gombotz, C., & Byrnes-Blake, K. (2018). Tozuleristide pharmacokinetics from phase 1 studies in adult and pediatric subjects with central nervous system tumors undergoing surgery.

Journal of Clinical Oncology, 36(15_suppl), e14562.

30 DrugBank. (n.d.).

Tozuleristide.

27 Butte, P. (n.d.).

Scientific Contributions. ResearchGate.

54 Zhang, L., et al. (2024). Venom-derived peptides for breaking through the glass ceiling of drug development.

ResearchGate.

55 Ghosh, A., Roy, R., Nandi, M., & Mukhopadhyay, A. (2019). Scorpion venom-toxins that aid in drug development: a review.

International Journal of Peptide Research and Therapeutics, 25(1), 27-37.

16 Synapse. (n.d.).

Blaze Bioscience, Inc. - Clinical Trials.

17 Leary, S., et al. (2020). A phase II/III randomized, blinded study of tozuleristide for fluorescence imaging detection during neurosurgical resection of pediatric primary central nervous system (CNS) tumors: PNOC012 (Pacific Pediatric Neuro-oncology Consortium).

Journal of Clinical Oncology, 38(15_suppl), TPS2575.

39 Business Wire. (2020, April 7).

Blaze Bioscience Announces FDA Has Granted Fast Track Designation to BLZ-100 (tozuleristide) for Pediatric Central Nervous System Tumors.

56 BioSpace. (2018, November 28).

Blaze Bioscience Announces the Initiation of Pivotal Clinical Trial for Tumor Paint: BLZ-100 (tozuleristide) and the Canvas Imaging System.

57 St. Jude Children's Research Hospital. (n.d.).

PEPN2415: AZD1390 for High-Grade Gliomas.

28 Patil, C. G., et al. (2019). Phase 1 Safety, Pharmacokinetics, and Fluorescence Imaging Study of Tozuleristide (BLZ-100) in Adults with Newly Diagnosed or Recurrent Gliomas.

Neurosurgery, 85(5), E641-E649.

58 National Brain Tumor Society. (n.d.).

A Phase 2 Study of Fluorescence Detection of Adult Primary Central Nervous System Tumors in Subjects Receiving Tozuleristide and Imaged with the Canvas System.

29 Larvol. (2018, May).

Safety Study of BLZ-100 in Adult Subjects With Glioma Undergoing Surgery.

45 NCATS. (n.d.).

Tozuleristide.

46 NCATS Inxight Drugs. (n.d.).

TOZULERISTIDE.

59 Onclive. (2025, February 12).

FDA Grants Orphan Drug Designation to OPN-6602 for R/R Multiple Myeloma.

60 ASCO Post. (2020, April 10).

FDA Pipeline: Priority Reviews for Immunotherapy Based on Biomarker Status, Combination First-Line Therapy in Lung Cancer.

48 GeekWire. (2020, April 7).

Blaze Bioscience gets Fast Track approval from FDA for 'Tumor Paint' that helps remove brain tumors.

49 FirstWord Pharma. (n.d.).

Tozuleristide News & Analysis.

61 European Medicines Agency. (2021, February 15).

EU/3/20/2357: Public summary of opinion on orphan designation - Tislelizumab for the treatment of oesophageal cancer.

62 European Medicines Agency. (n.d.).

Orphan designation: Overview.

63 Wang, T., et al. (2022). A Novel 99mTc-Labeled Chlorotoxin-Based SPECT/CT Imaging Agent for Glioma.

Journal of Nuclear Medicine, 63(11), 1620-1626.

40 Santarius, T., et al. (2024). Fluorescence-Guided Surgery for High-Grade Glioma: A Comparative Analysis of 5-ALA and Conventional White-Light Resection.

Cancers, 17(12), 2019.

41 Santarius, T., et al. (2024). Fluorescence-Guided Surgery for High-Grade Glioma: A Comparative Analysis of 5-ALA and Conventional White-Light Resection.

Cancers, 17(12), 2019.

1 Valdes, P. A., & Roberts, D. W. (n.d.). Tozuleristide Fluorescence-Guided Surgery of Brain Tumors.

Neupsy Key.

64 University of Pittsburgh Department of Neurological Surgery. (n.d.).

Fluorescence-Guided Surgery.

4 Warram, J. M., et al. (2019). Real-time fluorescence imaging for intraoperative decision making in head and neck cancer.

Journal of Nuclear Medicine, 60(5), 644-649.

5 NIHR. (n.d.).

A randomised controlled trial of fluorescence guided sarcoma surgery to improve outcomes for patients.

2 Zhao, H., et al. (2024). Optical Imaging Technology for In Vivo Tumor Detection.

ResearchGate.

28 Patil, C. G., et al. (2019). Phase 1 Safety, Pharmacokinetics, and Fluorescence Imaging Study of Tozuleristide (BLZ-100) in Adults With Newly Diagnosed or Recurrent Gliomas.

Neurosurgery, 85(5), E641-E649.

21 Wang, T., et al. (2022). A Novel 99mTc-Labeled Chlorotoxin-Based SPECT/CT Imaging Agent for Glioma.

Journal of Nuclear Medicine, 63(11), 1620-1626.

35 Leary, S., et al. (2020). A phase II/III randomized, blinded study of tozuleristide for fluorescence imaging detection during neurosurgical resection of pediatric primary central nervous system (CNS) tumors: PNOC012 (Pacific Pediatric Neuro-oncology Consortium).

Journal of Clinical Oncology, 38(15_suppl), TPS2575.

34 Mellinghoff, I. K., et al. (2020). INDIGO: A global, randomized, double-blind, phase III study of vorasidenib (VOR; AG-881) vs placebo in patients (pts) with residual or recurrent grade II glioma with an isocitrate dehydrogenase 1/2 (IDH1/2) mutation.

Journal of Clinical Oncology, 38(15_suppl), TPS2574.

31 Pacific Pediatric Neuro-Oncology Consortium. (n.d.).

PNOC012: Study of Tozuleristide and the Canvas Imaging System in Pediatric Subjects With CNS Tumors Undergoing Surgery.

8 Yamada, M., et al. (2021). A first-in-human study of BLZ-100 (tozuleristide) demonstrates tolerability and safety in skin cancer patients.

Contemporary Clinical Trials Communications, 23, 100830.

37 de Witte, S., et al. (2020). Overview of clinical trials in fluorescence-guided surgery.

Journal of Nuclear Medicine, 61(5), 637-643.

14 BioSpace. (2020, April 7).

Blaze Bioscience Announces FDA Has Granted Fast Track Designation to BLZ-100 (tozuleristide) for Pediatric Central Nervous System Tumors.

38 Blaze Bioscience. (n.d.).

Publications.

36 Blaze Bioscience. (n.d.).

Press Releases.

15 Synapse. (n.d.).

Tozuleristide - Drug Targets, Indications, Patents.

42 Singh, B., et al. (2025). The utility of 5-aminolevulinic acid fluorescence-guided surgery in paediatric brain tumours: a systematic review.

PubMed.

41 Santarius, T., et al. (2024). Fluorescence-Guided Surgery for High-Grade Glioma: A Comparative Analysis of 5-ALA and Conventional White-Light Resection.

Cancers, 17(12), 2019.

65 Frontiers in Oncology. (2025).

Multiforme glioblastoma-homing peptides.

66 ResearchGate. (2024).

Optical Imaging Technology for In Vivo Tumor Detection.

67 SPIE. (2025).

Molecular-Guided Surgery: Molecules, Devices, and Applications XI.

68 Journal of Biomedical Optics. (2024).

Fluorescence-guided surgery imaging systems for breast cancer identification: a systematic review.

50 U.S. Food and Drug Administration. (2024, January 29).

Pre-Notice of Noncompliance Letter to Blaze Bioscience Inc. (CDER-2024-116).

9 Business Wire. (2022, November 2).

Blaze Bioscience Announces Enrollment is Complete on its Pivotal Phase 2/3 Trial of tozuleristide and the CanvasTM Imaging System in Pediatric Central Nervous System Tumors.

12 BioSpace. (2018, November 28).

Blaze Bioscience Announces the Initiation of Pivotal Clinical Trial for Tumor Paint: BLZ-100 (tozuleristide) and the Canvas Imaging System.

13 Blaze Bioscience. (n.d.).

About Us.

47 Blaze Bioscience. (n.d.).

Press Releases - Archive.

16 Synapse. (n.d.).

Blaze Bioscience, Inc. - Clinical Trials.

6 National Cancer Institute. (n.d.).

NCI Drug Dictionary: Tozuleristide.

18 Szabo, I., et al. (2023). Chlorotoxin binds to both matrix metalloproteinase 2 and neuropilin 1.

Journal of Biological Chemistry, 299(9), 105151.

69 DrugBank. (n.d.).

Tozuleristide.

32 Yamada, M., et al. (2021). A first-in-human study of BLZ-100 (tozuleristide) demonstrates tolerability and safety in skin cancer patients.

Contemporary Clinical Trials Communications, 23, 100830.

19 Yamada, M., et al. (2021). A first-in-human study of BLZ-100 (tozuleristide) demonstrates tolerability and safety in skin cancer patients.

ResearchGate.

23 Deshane, J., et al. (2023). Chlorotoxin: A Promising Natural Targeting Peptide for Cancers.

Cancers, 15(13), 3388.

20 O'Connor, E., et al. (2021). Timing of Fluorophore Administration in Fluorescence-Guided Surgery for Glioma Patients.

Frontiers in Neurology, 12, 682151.

40 Santarius, T., et al. (2024). Fluorescence-Guided Surgery for High-Grade Glioma: A Comparative Analysis of 5-ALA and Conventional White-Light Resection.

Cancers, 17(12), 2019.

1 Valdes, P. A., & Roberts, D. W. (n.d.). Tozuleristide Fluorescence-Guided Surgery of Brain Tumors.

Neupsy Key.

43 D'Andrea, G., et al. (2023). How Reliable Is Fluorescence-Guided Surgery in Low-Grade Gliomas? A Systematic Review Concerning Different Fluorophores.

Cancers, 15(16), 4130.

51 D'Andrea, G., et al. (2023). How Reliable Is Fluorescence-Guided Surgery in Low-Grade Gliomas? A Systematic Review Concerning Different Fluorophores.

PubMed Central.

44 Hadjipanayis, C. G., et al. (2021). Fluorescence-guided surgery for high-grade glioma.

Journal of Neuro-Oncology, 153(1), 1-13.

15 Synapse. (n.d.).

Tozuleristide - Drug Targets, Indications, Patents.

35 Leary, S., et al. (2020). A phase II/III randomized, blinded study of tozuleristide for fluorescence imaging detection during neurosurgical resection of pediatric primary central nervous system (CNS) tumors: PNOC012 (Pacific Pediatric Neuro-oncology Consortium).

Journal of Clinical Oncology, 38(15_suppl), TPS2575.

17 Leary, S., et al. (2020). A phase II/III randomized, blinded study of tozuleristide for fluorescence imaging detection during neurosurgical resection of pediatric primary central nervous system (CNS) tumors: PNOC012 (Pacific Pediatric Neuro-oncology Consortium).

ResearchGate.

16 Synapse. (n.d.).

Blaze Bioscience, Inc. - Clinical Trials.

19 Yamada, M., et al. (2021). A first-in-human study of BLZ-100 (tozuleristide) demonstrates tolerability and safety in skin cancer patients.

ResearchGate.

70 ASCO. (2020).

AM20 - Central Nervous System Tumors.

71 Singhal, S., et al. (2022). Optical Imaging Technology for In Vivo Tumor Detection.

Journal of Nuclear Medicine, 63(11), 1620-1626.

2 Zhao, H., et al. (2024). Fluorescence-Guided Surgery for Gliomas: An Overview of Current Applications and Future Perspectives.

Molecules, 29(12), 2019.

31 Pacific Pediatric Neuro-Oncology Consortium. (n.d.).

PNOC012: Study of Tozuleristide and the Canvas Imaging System in Pediatric Subjects With CNS Tumors Undergoing Surgery.

72 Pacific Pediatric Neuro-Oncology Consortium. (n.d.).

Clinical Trials.

22 Wang, T., et al. (2022). A Novel 99mTc-Labeled Chlorotoxin-Based SPECT/CT Imaging Agent for Glioma.

Journal of Nuclear Medicine, 63(11), 1620-1626.

34 Mellinghoff, I. K., et al. (2020). INDIGO: A global, randomized, double-blind, phase III study of vorasidenib (VOR; AG-881) vs placebo in patients (pts) with residual or recurrent grade II glioma with an isocitrate dehydrogenase 1/2 (IDH1/2) mutation.

Journal of Clinical Oncology, 38(15_suppl), TPS2574.

28 Patil, C. G., et al. (2019). Phase 1 Safety, Pharmacokinetics, and Fluorescence Imaging Study of Tozuleristide (BLZ-100) in Adults with Newly Diagnosed or Recurrent Gliomas.

Neurosurgery, 85(5), E641-E649.

27 Butte, P. (n.d.).

Scientific Contributions. ResearchGate.

50 U.S. Food and Drug Administration. (2024, January 29).

Pre-Notice of Noncompliance Letter to Blaze Bioscience Inc. (CDER-2024-116).

14 BioSpace. (2020, April 7).

Blaze Bioscience Announces FDA Has Granted Fast Track Designation to BLZ-100 (tozuleristide) for Pediatric Central Nervous System Tumors.

41 Santarius, T., et al. (2024). Fluorescence-Guided Surgery for High-Grade Glioma: A Comparative Analysis of 5-ALA and Conventional White-Light Resection.

Cancers, 17(12), 2019.

36 Blaze Bioscience. (n.d.).

Press Releases.

73 Neuro Central. (2022, November 2).

Blaze Bioscience Announces Enrollment is Complete on its Pivotal Phase 2/3 Trial of tozuleristide and the CanvasTM Imaging System in Pediatric Central Nervous System Tumors.

32 Yamada, M., et al. (2021). A first-in-human study of BLZ-100 (tozuleristide) demonstrates tolerability and safety in skin cancer patients.

PubMed Central.

3 Santarius, T., et al. (2024). Fluorescence-Guided Surgery for High-Grade Glioma: A Comparative Analysis of 5-ALA and Conventional White-Light Resection.

Cancers, 17(12), 2019.

40 Santarius, T., et al. (2024). Fluorescence-Guided Surgery for High-Grade Glioma: A Comparative Analysis of 5-ALA and Conventional White-Light Resection.

Cancers, 17(12), 2019.

1 Valdes, P. A., & Roberts, D. W. (n.d.). Tozuleristide Fluorescence-Guided Surgery of Brain Tumors.

Neupsy Key.

74 O'Connor, E., et al. (2021). Timing of Fluorophore Administration in Fluorescence-Guided Surgery for Glioma Patients.

Frontiers in Neurology, 12, 674083.

75 Patil, C. G., et al. (2019). Phase 1 Safety, Pharmacokinetics, and Fluorescence Imaging Study of Tozuleristide (BLZ-100) in Adults With Newly Diagnosed or Recurrent Gliomas.

ResearchGate.

76 Yang, L., et al. (2024). Optical Imaging Technology for In Vivo Tumor Detection.

Biomaterials, 305, 122456.

18 Szabo, I., et al. (2023). Chlorotoxin binds to both matrix metalloproteinase 2 and neuropilin 1.

PubMed Central.

26 Szabo, I., et al. (2023). Chlorotoxin binds to both matrix metalloproteinase 2 and neuropilin 1.

ResearchGate.

24 Dardevet, L., et al. (2019). A peptide-drug conjugate, ER-472, targeting neuropilin-1 for the treatment of solid tumors.

Journal of Medicinal Chemistry, 62(13), 6125-6138.

77 DeBin, J. A., & Strichartz, G. R. (1993). Chloride channel-blocking properties of a peptide from scorpion venom.

American Journal of Physiology-Cell Physiology, 264(2), C361-C369.

25 Harrison, P. L., et al. (2021). Structural basis for the binding of the cancer targeting scorpion toxin ClTx to the vascular endothelial growth factor receptor neuropilin-1.

ResearchGate.

78 Ho, D., et al. (2021). Real-time fluorescence-guided surgery with a tumor-specific probe.

Frontiers in Oncology, 11, 674083.

79 Szabo, I., Bock, I., Juhasz, T., Hollo, K., Gonczi, M., Krizbai, I. A., & Deli, M. A. (2023). Chlorotoxin binds to both matrix metalloproteinase 2 and neuropilin 1.

Journal of Biological Chemistry, 299(9), 105151.

28 Patil, C. G., et al. (2019). Phase 1 Safety, Pharmacokinetics, and Fluorescence Imaging Study of Tozuleristide (BLZ-100) in Adults With Newly Diagnosed or Recurrent Gliomas.

Neurosurgery, 85(5), E641-E649.

31 Pacific Pediatric Neuro-Oncology Consortium. (n.d.).

PNOC012: Study of Tozuleristide and the Canvas Imaging System in Pediatric Subjects With CNS Tumors Undergoing Surgery.

28 Patil, C. G., et al. (2019). Phase 1 Safety, Pharmacokinetics, and Fluorescence Imaging Study of Tozuleristide (BLZ-100) in Adults with Newly Diagnosed or Recurrent Gliomas.

Neurosurgery, 85(5), E641-E649.

8 Yamada, M., et al. (2021). A first-in-human study of BLZ-100 (tozuleristide) demonstrates tolerability and safety in skin cancer patients.

Contemporary Clinical Trials Communications, 23, 100830.

50 U.S. Food and Drug Administration. (2024, January 29).

Pre-Notice of Noncompliance Letter to Blaze Bioscience Inc. (CDER-2024-116).

43 D'Andrea, G., et al. (2023). How Reliable Is Fluorescence-Guided Surgery in Low-Grade Gliomas? A Systematic Review Concerning Different Fluorophores.

Cancers, 15(16), 4130.# Comprehensive Report on Tozuleristide (BLZ-100): An Investigational Agent for Fluorescence-Guided Surgery

I. Executive Summary

Tozuleristide, also known by its investigational code BLZ-100, is a novel, first-in-class, injectable imaging agent under development by the privately held biotechnology company Blaze Bioscience, Inc. It is classified as a biotech product, specifically a peptide-dye conjugate, designed to provide real-time, intraoperative visualization of malignant tissue. The agent's structure comprises two key components: a synthetic variant of chlorotoxin (CTX), a peptide derived from scorpion venom that provides tumor-targeting specificity, and indocyanine green (ICG), a near-infrared (NIR) fluorescent dye that allows for tissue illumination. This dual-component design forms the basis of the company's "Tumor Paint®" platform technology.

The mechanism of action relies on the CTX moiety's ability to selectively bind to a constellation of proteins often overexpressed in the tumor microenvironment, including matrix metalloproteinase-2 (MMP-2) and neuropilin-1 (NRP1). This targeted binding leads to the accumulation and retention of Tozuleristide within cancerous tissue. Upon excitation with a compatible NIR imaging system, the ICG component fluoresces, enabling surgeons to visually differentiate tumor margins from surrounding healthy tissue with high precision.

Clinical development has demonstrated a favorable safety and tolerability profile across multiple Phase 1 trials in adults with glioma, skin cancer, and sarcoma, as well as in pediatric patients with central nervous system (CNS) tumors. A maximum tolerated dose has not been identified, and adverse events have been minimal. Pharmacokinetic studies reveal a short serum half-life, yet prolonged tumor fluorescence, providing strong evidence of specific target engagement and retention.

The most advanced clinical program is the pivotal Phase 2/3 PNOC012 trial (NCT03579602), which has completed enrollment of 123 pediatric patients with CNS tumors. This trial evaluates Tozuleristide in conjunction with the proprietary Canvas™ Imaging System, an integrated device designed for high-sensitivity NIR detection. The agent has received both Orphan Drug Designation and Fast Track Designation from the U.S. Food and Drug Administration (FDA) for its application in pediatric CNS tumors, highlighting the significant unmet need in this population.

However, the program faces a notable regulatory challenge. In January 2024, the FDA issued a Pre-Notice of Noncompliance to Blaze Bioscience for failure to submit the results of the completed PNOC012 trial to ClinicalTrials.gov within the mandated timeframe. This data gap creates uncertainty and represents a material risk for the program's advancement.

Competitively, Tozuleristide is positioned to address key limitations of existing fluorescence-guided surgery agents, particularly the limited efficacy of 5-aminolevulinic acid (5-ALA) in low-grade and pediatric gliomas. By demonstrating fluorescence in these specific tumor types, Tozuleristide has a clear opportunity to establish a strong clinical niche. The future success of Tozuleristide will depend on the timely publication of its pivotal trial data, resolution of the outstanding FDA compliance issue, and a viable commercialization strategy for its integrated drug-device system.

II. Introduction: The Clinical Imperative for Enhanced Intraoperative Visualization

The Challenge of Achieving Gross Total Resection (GTR) in Surgical Oncology

In the field of surgical oncology, the extent of resection is one of the most significant modifiable prognostic factors for a wide range of solid tumors. Achieving a gross total resection (GTR), where all visible cancerous tissue is removed, is directly correlated with improved progression-free survival and overall survival, particularly in neuro-oncology for the treatment of gliomas.[1] However, the infiltrative nature of many cancers, which lack clear demarcation from surrounding healthy tissue, makes GTR a formidable challenge for surgeons.

The current standard of care for tumor resection relies heavily on preoperative imaging such as MRI, intraoperative visual cues under white light, and the surgeon's tactile feedback (palpation).[4] These methods have inherent limitations. Preoperative imaging loses accuracy due to "brain shift" once surgery commences, and visual inspection alone is often insufficient to detect microscopic residual disease at the tumor margins.[1] This reliance on subjective assessment contributes to a high rate of positive surgical margins, where cancer cells are left behind, a primary driver of local recurrence and treatment failure.[4]

Overview of Tozuleristide (BLZ-100) as a Novel, Targeted Imaging Agent

To address this critical unmet need, a new class of intraoperative imaging agents is emerging to enhance surgical precision. Tozuleristide (BLZ-100) is a first-in-class investigational agent at the forefront of this field. Developed by Blaze Bioscience, Tozuleristide is a tumor-targeting fluorescent agent designed to provide surgeons with real-time, high-resolution visualization of cancer cells during an operation.[6] Marketed under the "Tumor Paint" concept, the agent is engineered to selectively accumulate in malignant tissue, which then "glows" under near-infrared light, allowing for a clear distinction between tumor and healthy tissue.[7] This technology aims to transform surgical oncology by enabling more complete and safer resections, thereby improving patient outcomes.

Developer Profile: Blaze Bioscience

Tozuleristide is being developed by Blaze Bioscience, Inc., a privately held biotechnology company based in Seattle, Washington, that is singularly focused on improving the lives of cancer patients through its Tumor Paint® platform.[7] The company was founded in 2010 by Dr. Jim Olson, a pediatric neuro-oncologist at the Fred Hutchinson Cancer Research Center and Seattle Children's Hospital, and Heather Franklin, a seasoned biotechnology executive.[9] This foundation provides the company with deep scientific credibility and a clear clinical focus. Integral to the Tozuleristide program is the development of the Canvas™ Imaging System, a proprietary device created by Teal Light Surgical, Inc., a wholly-owned subsidiary of Blaze Bioscience, highlighting the company's integrated drug-device strategy.[9]

III. Scientific Foundation and Mechanism of Action

A Dual-Component Conjugate: Structure and Function

Tozuleristide is a biologic drug classified as a peptide-dye conjugate. Its innovative design comprises two distinct functional moieties covalently linked to form a single agent capable of both targeting and illuminating cancer cells.[6]

The Targeting Moiety: Chlorotoxin (CTX)

The tumor-targeting capability of Tozuleristide is conferred by its peptide component, a synthetic variant of chlorotoxin (CTX).[16] Natural CTX is a 36-amino acid peptide neurotoxin isolated from the venom of the Israeli deathstalker scorpion,

Leiurus quinquestriatus.[6] Decades of research have established that CTX possesses a remarkable and inherent ability to selectively bind to a wide array of cancer cells, particularly those of neuroectodermal origin, such as gliomas, sarcomas, and melanomas, while showing minimal affinity for non-cancerous cells.[6] This tumor-specific binding is the cornerstone of the "Tumor Paint" platform, guiding the fluorescent payload directly to the site of malignancy.

The Imaging Moiety: Indocyanine Green (ICG)

The visualization component of Tozuleristide is indocyanine green (ICG), a well-characterized fluorescent dye.[6] ICG is excited by and emits light in the near-infrared (NIR) spectrum (approximately 700–850 nm).[1] The use of NIR light for in vivo imaging offers several distinct advantages over visible-light fluorophores like 5-ALA. NIR light experiences significantly less absorption and scattering by biological tissues, such as blood and water, allowing for deeper tissue penetration and a much lower background signal from endogenous autofluorescence.[1] This results in a superior signal-to-background ratio, which is critical for clearly delineating tumor margins, especially in deep-seated or highly vascularized tissues like the brain.

Elucidating the Cellular Binding Targets: A Critical Review of the Evidence

While the tumor-targeting ability of CTX is empirically established, its precise molecular binding mechanism has been a subject of scientific investigation and debate, with several proteins proposed as potential targets.

The Role of Matrix Metalloproteinase-2 (MMP-2)

Early research suggested that the tumor selectivity of CTX was due to its interaction with matrix metalloproteinase-2 (MMP-2), a zinc-dependent endopeptidase.[18] MMP-2 is frequently overexpressed in the tumor microenvironment of many cancers, including glioma, and plays a crucial role in degrading the extracellular matrix, which facilitates tumor invasion and metastasis.[23] The hypothesis was that CTX binds to MMP-2, possibly as part of a larger membrane-associated complex that includes other proteins like MMP-14 and αvβ3 integrin, thereby anchoring the imaging agent to the tumor cell surface.[18] Some reports even claimed that CTX binding inhibited MMP-2 activity, suggesting a potential therapeutic effect in addition to its diagnostic function.[18]

Investigating Annexin A2 (ANX2) and Neuropilin-1 (NRP1)

The MMP-2 binding hypothesis was subsequently challenged. A follow-up study using a pull-down assay failed to detect a direct and specific interaction between labeled CTX and recombinant MMP-2, casting doubt on its role as the primary receptor.[18] This ambiguity prompted further investigation, leading to the proposal of annexin A2 (ANX2), a calcium-dependent phospholipid-binding protein, as an alternative binding partner.[18]

More recently, another research group identified neuropilin-1 (NRP1) as a novel CTX target.[18] NRP1 is an endocytic receptor found on tumor and endothelial cells that is involved in angiogenesis and tumor progression. Subsequent biochemical studies have confirmed a strong interaction between CTX and both MMP-2 and NRP1, while failing to confirm binding to ANX2.[18]

Synthesis of Current Understanding

The collective body of evidence suggests that the tumor-targeting mechanism of CTX is not mediated by a single, exclusive receptor but is likely a multifactorial process. The ability of CTX to bind to a range of different proteins, such as MMP-2 and NRP1, which are commonly upregulated in the pathological microenvironment of diverse tumors, may explain its broad applicability across different cancer types.[18] This promiscuous yet tumor-selective binding profile may be the key to its function as a pan-tumor imaging agent. While this molecular ambiguity could present a challenge from a narrow regulatory perspective, it appears to be a functional strength, allowing Tozuleristide to effectively "paint" a variety of solid tumors.

The development of Tozuleristide as the first product from the "Tumor Paint®" platform signifies a broader strategic approach by Blaze Bioscience.[9] This platform is modular, consisting of a targeting peptide and a functional payload. This framework allows for future innovation by potentially swapping either component. For instance, different peptides could be used to target other cellular markers, or the ICG payload could be replaced with a therapeutic agent, transforming the platform from a diagnostic to a therapeutic tool. Tozuleristide thus serves as a critical proof-of-concept for this versatile technology.

IV. Preclinical and Clinical Development Program

The clinical development of Tozuleristide has been systematic, progressing from foundational safety studies in accessible tumors to pivotal trials in its primary target indication of pediatric CNS tumors. The program has consistently demonstrated a favorable safety profile and promising imaging capabilities.

Table 1: Summary of Key Tozuleristide Clinical Trials
NCT Number
NCT02097875
NCT02234297
NCT02464332
NCT03579602
NCT04743310
NCT05316688

Early Human Studies: Safety, Tolerability, and Pharmacokinetics

The first-in-human trial of Tozuleristide (NCT02097875) was conducted in 21 adult patients with known or suspected skin cancers, including basal cell carcinoma and melanoma.[8] This population was selected for its accessibility, allowing for non-invasive imaging to assess pharmacodynamics. The study established a strong foundational safety profile. Tozuleristide was well-tolerated at intravenous doses up to 18 mg, and a maximum tolerated dose (MTD) was not identified. There were no serious adverse events, deaths, or discontinuations due to adverse events. The only treatment-related adverse events reported in more than one patient were mild headache and nausea.[8] Critically, the study also provided the first human proof-of-concept for imaging, with positive fluorescence observed in 4 of 5 basal cell carcinomas and 4 of 4 melanomas at intermediate dose levels.[8]

Pharmacokinetic (PK) analyses from these early Phase 1 studies in both adult and pediatric populations revealed a consistent and important characteristic of the drug.[28] Tozuleristide exhibits a very short serum half-life (

t1/2​) of approximately 30 minutes. However, tumor-specific fluorescence has been observed from as early as 3-4 hours to as late as 27-48 hours post-administration.[28] This disconnect between the drug's rapid clearance from circulation and its prolonged retention in malignant tissue is a key finding. It strongly suggests that Tozuleristide is not merely passively accumulating due to vascular leakiness but is actively binding to and being retained by specific targets within the tumor, providing robust validation for its targeted mechanism of action.

Application in Neurosurgery: Glioma and CNS Tumors

Building on the initial safety data, the clinical program advanced into neuro-oncology. A Phase 1 dose-escalation study in 17 adults with newly diagnosed or recurrent glioma (NCT02234297) further confirmed the agent's safety at doses up to 30 mg.[11] This trial demonstrated that Tozuleristide could effectively illuminate both high-grade and low-grade gliomas, with the fluorescence intensity in high-grade tumors increasing in a dose-dependent manner.[28]

The program's most significant undertaking is the pivotal Phase 2/3 PNOC012 trial (NCT03579602). This randomized, blinded study enrolled 123 pediatric and young adult patients (ages 1 month to 30 years) with CNS tumors.[9] The trial was designed to rigorously evaluate the efficacy of Tozuleristide and the Canvas™ Imaging System compared to standard of care surgery without fluorescence guidance. The primary endpoints were designed to measure the sensitivity and specificity of fluorescence in identifying tumor tissue in surgically equivocal regions, while secondary endpoints included the extent of resection (EOR) and safety.[31] Blaze Bioscience announced the completion of enrollment for this pivotal trial in November 2022, a major milestone for the program.[9] The results of this study are highly anticipated and will be critical for any future regulatory submissions.

Investigation in Sarcoma (NCT02464332)

According to the DrugBank database, Tozuleristide was investigated in a Phase 1 safety study involving adult subjects with sarcoma undergoing surgery (NCT02464332).[30] However, a comprehensive search of published literature and conference proceedings did not yield any results, abstracts, or presentations related to this specific trial.[8] This absence of data represents a notable gap in the public understanding of Tozuleristide's development history. This could be attributable to several factors, including the possibility of neutral or unfavorable results, a strategic decision by the company to deprioritize the sarcoma indication in favor of the more advanced CNS tumor program, or simply a delay in publication. For potential investors or partners, this data gap is a point that requires clarification.

Exploration in Other Solid Tumors

Beyond the formally registered trials, Tozuleristide has demonstrated preclinical or early clinical proof-of-concept in a range of other solid tumors, including breast cancer.[7] The company has also indicated potential applications in prostate, head and neck, and colorectal cancers, suggesting a broad market potential for the Tumor Paint® platform technology.[7]

V. The Canvas™ Imaging System: An Integrated Technology

Device Overview and Role in NIR Fluorescence Detection

The clinical utility of Tozuleristide is dependent on a specialized imaging device capable of detecting its NIR signal. To this end, Blaze Bioscience's wholly-owned subsidiary, Teal Light Surgical, Inc., developed the Canvas™ Imaging System.[9] The Canvas system is an investigational medical device engineered to provide high-sensitivity detection of NIR light. A key design feature is its ability to function effectively under the ambient light conditions of a standard operating room, which represents a significant advantage in usability and workflow integration for surgeons.[9] The initial version of the device is adapted for seamless integration with surgical microscopes, the primary visualization tool in neurosurgery.[12]

Synergy with Tozuleristide

Tozuleristide and the Canvas system are not standalone products but are being developed and tested as a cohesive, integrated drug-device combination.[9] The success of the imaging agent is inextricably linked to the performance of the imaging system. The high sensitivity of the Canvas system is required to detect the specific, and potentially low, levels of fluorescence generated by a targeted agent like Tozuleristide, as opposed to the brighter, non-specific signals from passive dyes. This synergy was a central component of the pivotal PNOC012 trial design, which assessed the efficacy of the combined system.[31]

This integrated approach presents both challenges and strategic advantages. The development pathway for a drug-device combination is inherently more complex, time-consuming, and costly than for a drug alone, as it requires navigating regulatory pathways for both components. However, should this system achieve regulatory approval, it would establish a formidable competitive moat. A competitor would need to develop not only a biosimilar imaging agent but also a compatible, high-performance imaging system to rival the Blaze platform. By co-developing and optimizing the device specifically for Tozuleristide, Blaze has created a proprietary ecosystem that would be difficult for others to replicate, thus protecting its market position.

VI. Regulatory and Competitive Landscape

Tozuleristide is entering a dynamic field of fluorescence-guided surgery (FGS) with established players and distinct clinical needs. Its regulatory pathway has been facilitated by key FDA designations, but is also marked by a recent compliance issue.

Table 2: Comparative Analysis of Intraoperative Fluorescent Agents in Glioma Surgery
Agent
Tozuleristide (BLZ-100)
5-Aminolevulinic Acid (5-ALA)
Fluorescein Sodium
Indocyanine Green (ICG)

FDA Designations

Blaze Bioscience has successfully secured two important designations from the U.S. FDA that facilitate and expedite the development of Tozuleristide.

• Orphan Drug Designation (ODD): Tozuleristide was granted ODD for its use as a "Diagnostic for the management of malignant brain tumors".[45] This designation is granted to therapies addressing rare diseases or conditions affecting fewer than 200,000 people in the U.S. and provides incentives such as tax credits for clinical trials, exemption from user fees, and the potential for seven years of market exclusivity upon approval.
• Fast Track Designation: In April 2020, the FDA granted Fast Track designation to the Tozuleristide program for pediatric CNS tumors.[14] This designation is intended to facilitate the development and expedite the review of drugs that treat serious conditions and fill an unmet medical need, allowing for more frequent meetings with the FDA and eligibility for accelerated approval and priority review.

Regulatory Correspondence: The FDA Letter on NCT03579602

A significant event in the regulatory history of Tozuleristide occurred on January 29, 2024, when the FDA's Center for Drug Evaluation and Research (CDER) issued a "Pre-Notice of Noncompliance" letter to Blaze Bioscience.[50] The letter explicitly states that the company appears to have failed to submit the required results information for the pivotal PNOC012 trial (NCT03579602) to the ClinicalTrials.gov data bank within the one-year statutory deadline following the trial's primary completion date.

The letter serves as a formal warning, requesting that Blaze Bioscience review its records and submit the required information promptly. It outlines the potential consequences of continued non-compliance, which include a formal Notice of Noncompliance and the potential for civil monetary penalties of up to $10,000 per day until the violation is corrected.[50]

For a private, clinical-stage company like Blaze Bioscience, this public letter represents a material risk. Beyond the potential financial penalties, it raises questions regarding the company's operational and regulatory discipline. For potential investors or pharmaceutical partners conducting due diligence, such a finding can be a significant red flag, creating uncertainty about the reasons for the delay in data disclosure. The timely resolution of this issue and the transparent publication of the pivotal trial data are critical for the program's continued progress and for maintaining credibility with regulatory bodies and the investment community.

The competitive positioning of Tozuleristide appears most robust in the areas where current standards are weakest. The literature consistently demonstrates that 5-ALA, the current standard for FGS in gliomas, has a very low rate of visible fluorescence in low-grade gliomas (LGGs), with one systematic review reporting a positivity rate of only 7.3%.[40] In contrast, Phase 1 data for Tozuleristide have shown detectable fluorescence in LGGs.[28] This capability positions Tozuleristide to fill a significant clinical gap. This is particularly relevant in the pediatric population, where LGGs are more common and for which the agent has received Fast Track designation.[39] This suggests a clear initial market strategy: targeting patient populations where it can offer a distinct advantage over the established standard of care, rather than competing directly with 5-ALA in its strongest indication of high-grade adult gliomas.

VII. Strategic Analysis and Future Outlook

Consolidated Strengths, Weaknesses, Opportunities, and Threats (SWOT) Analysis

• Strengths:
• Novel, Targeted Mechanism: The peptide-dye conjugate platform provides tumor-specific binding, a key differentiator from passive dyes.[6]
• Favorable Safety Profile: Multiple Phase 1 trials have shown Tozuleristide to be well-tolerated with minimal adverse events.[8]
• Broad Applicability: Demonstrated fluorescence across multiple tumor types (glioma, skin, sarcoma, breast) suggests pan-tumor potential.[9]
• Integrated Imaging System: The co-developed Canvas system creates a proprietary, high-performance ecosystem, raising the barrier to entry for competitors.[9]
• Weaknesses:
• Ambiguous Molecular Target: The lack of a single, definitively confirmed binding partner for CTX could be a point of scientific and regulatory scrutiny.[18]
• Data Gap in Sarcoma: The absence of published results from the NCT02464332 sarcoma trial creates uncertainty about its efficacy in that indication.[30]
• Drug-Device Complexity: The requirement for dual regulatory approval for both the drug and the device increases development complexity and cost.[9]
• Opportunities:
• Unmet Need in LGG and Pediatrics: Tozuleristide's ability to illuminate low-grade and pediatric CNS tumors addresses a major limitation of the current standard, 5-ALA.[40]
• Platform Technology Expansion: The "Tumor Paint" concept allows for the development of future agents with different targeting peptides or therapeutic payloads.[9]
• Improved Surgical Outcomes: If proven to increase GTR rates, Tozuleristide could become a new standard of care, improving patient survival and quality of life.
• Threats:
• FDA Regulatory Scrutiny: The Pre-Notice of Noncompliance letter for delayed data submission is a significant regulatory risk that could impact future interactions and partnerships.[50]
• Competition: While it has a niche, it will still compete with established FGS agents and other emerging imaging technologies.[40]
• Commercialization Hurdles: Establishing reimbursement and market access for a novel drug-device combination can be challenging.

Key Unanswered Questions and Development Hurdles

The future trajectory of Tozuleristide hinges on the resolution of several critical questions:

1. What are the final efficacy and safety results from the pivotal PNOC012 trial? The public release of this data is the single most important near-term catalyst for the program.
2. What were the findings of the NCT02464332 sarcoma study? Clarification on why these results were never published is necessary to fully assess the agent's potential breadth of application.
3. How will Blaze Bioscience address the FDA's non-compliance letter? The company's response and the subsequent FDA action will be a key indicator of its regulatory standing and operational capabilities.
4. What is the commercialization strategy? The company needs to articulate a clear plan for pricing, reimbursement, and market adoption for the integrated Tozuleristide and Canvas system.

Recommendations for Future Research and Clinical Strategy

To maximize the potential of the Tozuleristide program, the following strategic steps are recommended:

1. Prioritize Regulatory Compliance and Transparency: Immediately address the FDA's concerns by submitting the complete results of the PNOC012 trial to ClinicalTrials.gov and preparing the data for peer-reviewed publication. This is essential to restore confidence and clear the path for future regulatory submissions.
2. Focus on the Core Clinical Niche: Double down on the development and regulatory strategy for pediatric CNS tumors and low-grade gliomas, where Tozuleristide holds the clearest competitive advantage over 5-ALA.
3. Conduct Comparative Effectiveness Research: Once approved, or in a future trial, conduct head-to-head studies directly comparing Tozuleristide/Canvas with 5-ALA in LGG to generate definitive evidence of clinical superiority, which would be crucial for market adoption and reimbursement negotiations.
4. Further Elucidate the Mechanism of Action: Continue research into the binding targets of CTX. Identifying predictive biomarkers (e.g., high expression of NRP1 or MMP-2) could allow for better patient selection and potentially lead to companion diagnostic development, further strengthening the platform's value proposition.

VIII. References

[15] Synapse. (n.d.).

Tozuleristide - Drug Targets, Indications, Patents.

6 National Cancer Institute. (n.d.).

NCI Drug Dictionary: Tozuleristide.

52 AdisInsight. (2025, April 21).

Tozuleristide - Blaze Bioscience.

7 Synapse. (n.d.).

What is Tozuleristide used for?.

8 Yamada, M., Miller, D. M., Lowe, M., Rowe, C., Wood, D., Soyer, H. P., Byrnes-Blake, K., Parrish-Novak, J., Ishak, L., Olson, J. M., Brandt, G., Griffin, P., Spelman, L., & Prow, T. W. (2021). A first-in-human study of BLZ-100 (tozuleristide) demonstrates tolerability and safety in skin cancer patients.

Contemporary Clinical Trials Communications, 23, 100830.

9 Business Wire. (2022, November 2).

Blaze Bioscience Announces Enrollment is Complete on its Pivotal Phase 2/3 Trial of tozuleristide and the CanvasTM Imaging System in Pediatric Central Nervous System Tumors.

36 Blaze Bioscience. (n.d.).

Press Releases.

18 Szabo, I., Bock, I., Juhasz, T., Hollo, K., Gonczi, M., Krizbai, I. A., & Deli, M. A. (2023). Chlorotoxin binds to both matrix metalloproteinase 2 and neuropilin 1.

Journal of Biological Chemistry, 299(9), 105151.

20 O'Connor, E., et al. (2021). Timing of Fluorophore Administration in Fluorescence-Guided Surgery for Glioma Patients.

Frontiers in Neurology, 12, 682151.

10 Oregon State University Libraries. (n.d.).

A first-in-human study of BLZ-100 (tozuleristide) demonstrates tolerability and safety in skin cancer patients.

11 BioSpace. (2019, May 9).

Blaze Bioscience Announces the Publication of Phase 1 Clinical Trial Results for Tumor Paint: BLZ-100 (tozuleristide) in Adults with Glioma.

33 Miller, D. M., Leary, S., Lee, A., Patil, C., Walker, D., Ishak, L., Gombotz, C., & Byrnes-Blake, K. (2018). Tozuleristide pharmacokinetics from phase 1 studies in adult and pediatric subjects with central nervous system tumors undergoing surgery.

Journal of Clinical Oncology, 36(15_suppl), e14562.

30 DrugBank. (n.d.).

Tozuleristide.

27 Butte, P. (n.d.).

Scientific Contributions. ResearchGate.

16 Synapse. (n.d.).

Blaze Bioscience, Inc. - Clinical Trials.

17 Leary, S., et al. (2020). A phase II/III randomized, blinded study of tozuleristide for fluorescence imaging detection during neurosurgical resection of pediatric primary central nervous system (CNS) tumors: PNOC012 (Pacific Pediatric Neuro-oncology Consortium).

Journal of Clinical Oncology, 38(15_suppl), TPS2575.

39 Business Wire. (2020, April 7).

Blaze Bioscience Announces FDA Has Granted Fast Track Designation to BLZ-100 (tozuleristide) for Pediatric Central Nervous System Tumors.

56 BioSpace. (2018, November 28).

Blaze Bioscience Announces the Initiation of Pivotal Clinical Trial for Tumor Paint: BLZ-100 (tozuleristide) and the Canvas Imaging System.

28 Patil, C. G., et al. (2019). Phase 1 Safety, Pharmacokinetics, and Fluorescence Imaging Study of Tozuleristide (BLZ-100) in Adults with Newly Diagnosed or Recurrent Gliomas.

Neurosurgery, 85(5), E641-E649.

29 Larvol. (2018, May).

Safety Study of BLZ-100 in Adult Subjects With Glioma Undergoing Surgery.

45 NCATS. (n.d.).

Tozuleristide.

46 NCATS Inxight Drugs. (n.d.).

TOZULERISTIDE.

48 GeekWire. (2020, April 7).

Blaze Bioscience gets Fast Track approval from FDA for 'Tumor Paint' that helps remove brain tumors.

49 FirstWord Pharma. (n.d.).

Tozuleristide News & Analysis.

40 Santarius, T., et al. (2024). Fluorescence-Guided Surgery for High-Grade Glioma: A Comparative Analysis of 5-ALA and Conventional White-Light Resection.

Cancers, 17(12), 2019.

41 Santarius, T., et al. (2024). Fluorescence-Guided Surgery for High-Grade Glioma: A Comparative Analysis of 5-ALA and Conventional White-Light Resection.

Cancers, 17(12), 2019.

1 Valdes, P. A., & Roberts, D. W. (n.d.). Tozuleristide Fluorescence-Guided Surgery of Brain Tumors.

Neupsy Key.

4 Warram, J. M., et al. (2019). Real-time fluorescence imaging for intraoperative decision making in head and neck cancer.

Journal of Nuclear Medicine, 60(5), 644-649.

5 NIHR. (n.d.).

A randomised controlled trial of fluorescence guided sarcoma surgery to improve outcomes for patients.

2 Zhao, H., et al. (2024). Optical Imaging Technology for In Vivo Tumor Detection.

ResearchGate.

28 Patil, C. G., et al. (2019). Phase 1 Safety, Pharmacokinetics, and Fluorescence Imaging Study of Tozuleristide (BLZ-100) in Adults with Newly Diagnosed or Recurrent Gliomas.

Neurosurgery, 85(5), E641-E649.

21 Wang, T., et al. (2022). A Novel 99mTc-Labeled Chlorotoxin-Based SPECT/CT Imaging Agent for Glioma.

Journal of Nuclear Medicine, 63(11), 1620-1626.

35 Leary, S., et al. (2020). A phase II/III randomized, blinded study of tozuleristide for fluorescence imaging detection during neurosurgical resection of pediatric primary central nervous system (CNS) tumors: PNOC012 (Pacific Pediatric Neuro-oncology Consortium).

Journal of Clinical Oncology, 38(15_suppl), TPS2575.

34 Mellinghoff, I. K., et al. (2020). INDIGO: A global, randomized, double-blind, phase III study of vorasidenib (VOR; AG-881) vs placebo in patients (pts) with residual or recurrent grade II glioma with an isocitrate dehydrogenase 1/2 (IDH1/2) mutation.

Journal of Clinical Oncology, 38(15_suppl), TPS2574.

31 Pacific Pediatric Neuro-Oncology Consortium. (n.d.).

PNOC012: Study of Tozuleristide and the Canvas Imaging System in Pediatric Subjects With CNS Tumors Undergoing Surgery.

8 Yamada, M., et al. (2021). A first-in-human study of BLZ-100 (tozuleristide) demonstrates tolerability and safety in skin cancer patients.

Contemporary Clinical Trials Communications, 23, 100830.

37 de Witte, S., et al. (2020). Overview of clinical trials in fluorescence-guided surgery.

Journal of Nuclear Medicine, 61(5), 637-643.

14 BioSpace. (2020, April 7).

Blaze Bioscience Announces FDA Has Granted Fast Track Designation to BLZ-100 (tozuleristide) for Pediatric Central Nervous System Tumors.

36 Blaze Bioscience. (n.d.).

Press Releases.

42 Singh, B., et al. (2025). The utility of 5-aminolevulinic acid fluorescence-guided surgery in paediatric brain tumours: a systematic review.

PubMed.

50 U.S. Food and Drug Administration. (2024, January 29).

Pre-Notice of Noncompliance Letter to Blaze Bioscience Inc. (CDER-2024-116).

9 Business Wire. (2022, November 2).

Blaze Bioscience Announces Enrollment is Complete on its Pivotal Phase 2/3 Trial of tozuleristide and the CanvasTM Imaging System in Pediatric Central Nervous System Tumors.

12 BioSpace. (2018, November 28).

Blaze Bioscience Announces the Initiation of Pivotal Clinical Trial for Tumor Paint: BLZ-100 (tozuleristide) and the Canvas Imaging System.

13 Blaze Bioscience. (n.d.).

About Us.

47 Blaze Bioscience. (n.d.).

Press Releases - Archive.

16 Synapse. (n.d.).

Blaze Bioscience, Inc. - Clinical Trials.

18 Szabo, I., et al. (2023). Chlorotoxin binds to both matrix metalloproteinase 2 and neuropilin 1.

Journal of Biological Chemistry, 299(9), 105151.

32 Yamada, M., et al. (2021). A first-in-human study of BLZ-100 (tozuleristide) demonstrates tolerability and safety in skin cancer patients.

Contemporary Clinical Trials Communications, 23, 100830.

19 Yamada, M., et al. (2021). A first-in-human study of BLZ-100 (tozuleristide) demonstrates tolerability and safety in skin cancer patients.

ResearchGate.

23 Deshane, J., et al. (2023). Chlorotoxin: A Promising Natural Targeting Peptide for Cancers.

Cancers, 15(13), 3388.

20 O'Connor, E., et al. (2021). Timing of Fluorophore Administration in Fluorescence-Guided Surgery for Glioma Patients.

Frontiers in Neurology, 12, 674083.

40 Santarius, T., et al. (2024). Fluorescence-Guided Surgery for High-Grade Glioma: A Comparative Analysis of 5-ALA and Conventional White-Light Resection.

Cancers, 17(12), 2019.

1 Valdes, P. A., & Roberts, D. W. (n.d.). Tozuleristide Fluorescence-Guided Surgery of Brain Tumors.

Neupsy Key.

43 D'Andrea, G., et al. (2023). How Reliable Is Fluorescence-Guided Surgery in Low-Grade Gliomas? A Systematic Review Concerning Different Fluorophores.

Cancers, 15(16), 4130.

51 D'Andrea, G., et al. (2023). How Reliable Is Fluorescence-Guided Surgery in Low-Grade Gliomas? A Systematic Review Concerning Different Fluorophores.

PubMed Central.

44 Hadjipanayis, C. G., et al. (2021). Fluorescence-guided surgery for high-grade glioma.

Journal of Neuro-Oncology, 153(1), 1-13.

19 Yamada, M., et al. (2021). A first-in-human study of BLZ-100 (tozuleristide) demonstrates tolerability and safety in skin cancer patients.

ResearchGate.

28 Patil, C. G., et al. (2019). Phase 1 Safety, Pharmacokinetics, and Fluorescence Imaging Study of Tozuleristide (BLZ-100) in Adults with Newly Diagnosed or Recurrent Gliomas.

Neurosurgery, 85(5), E641-E649.

27 Butte, P. (n.d.).

Scientific Contributions. ResearchGate.

50 U.S. Food and Drug Administration. (2024, January 29).

Pre-Notice of Noncompliance Letter to Blaze Bioscience Inc. (CDER-2024-116).

3 Santarius, T., et al. (2024). Fluorescence-Guided Surgery for High-Grade Glioma: A Comparative Analysis of 5-ALA and Conventional White-Light Resection.

Cancers, 17(12), 2019.

40 Santarius, T., et al. (2024). Fluorescence-Guided Surgery for High-Grade Glioma: A Comparative Analysis of 5-ALA and Conventional White-Light Resection.

Cancers, 17(12), 2019.

1 Valdes, P. A., & Roberts, D. W. (n.d.). Tozuleristide Fluorescence-Guided Surgery of Brain Tumors.

Neupsy Key.

74 O'Connor, E., et al. (2021). Timing of Fluorophore Administration in Fluorescence-Guided Surgery for Glioma Patients.

Frontiers in Neurology, 12, 674083.

75 Patil, C. G., et al. (2019). Phase 1 Safety, Pharmacokinetics, and Fluorescence Imaging Study of Tozuleristide (BLZ-100) in Adults with Newly Diagnosed or Recurrent Gliomas.

ResearchGate.

18 Szabo, I., et al. (2023). Chlorotoxin binds to both matrix metalloproteinase 2 and neuropilin 1.

PubMed Central.

26 Szabo, I., et al. (2023). Chlorotoxin binds to both matrix metalloproteinase 2 and neuropilin 1.

ResearchGate.

24 Dardevet, L., et al. (2019). A peptide-drug conjugate, ER-472, targeting neuropilin-1 for the treatment of solid tumors.

Journal of Medicinal Chemistry, 62(13), 6125-6138.

25 Harrison, P. L., et al. (2021). Structural basis for the binding of the cancer targeting scorpion toxin ClTx to the vascular endothelial growth factor receptor neuropilin-1.

ResearchGate.

79 Szabo, I., Bock, I., Juhasz, T., Hollo, K., Gonczi, M., Krizbai, I. A., & Deli, M. A. (2023). Chlorotoxin binds to both matrix metalloproteinase 2 and neuropilin 1.

Journal of Biological Chemistry, 299(9), 105151.

28 Patil, C. G., et al. (2019). Phase 1 Safety, Pharmacokinetics, and Fluorescence Imaging Study of Tozuleristide (BLZ-100) in Adults with Newly Diagnosed or Recurrent Gliomas.

Neurosurgery, 85(5), E641-E649.

31 Pacific Pediatric Neuro-Oncology Consortium. (n.d.).

PNOC012: Study of Tozuleristide and the Canvas Imaging System in Pediatric Subjects With CNS Tumors Undergoing Surgery.

8 Yamada, M., et al. (2021). A first-in-human study of BLZ-100 (tozuleristide) demonstrates tolerability and safety in skin cancer patients.

Contemporary Clinical Trials Communications, 23, 100830.

50 U.S. Food and Drug Administration. (2024, January 29).

Pre-Notice of Noncompliance Letter to Blaze Bioscience Inc. (CDER-2024-116).

43 D'Andrea, G., et al. (2023). How Reliable Is Fluorescence-Guided Surgery in Low-Grade Gliomas? A Systematic Review Concerning Different Fluorophores.

Cancers, 15(16), 4130.

Works cited

1. Tozuleristide Fluorescence-Guided Surgery of Brain Tumors | Neupsy Key, accessed June 19, 2025, https://neupsykey.com/tozuleristide-fluorescence-guided-surgery-of-brain-tumors/
2. Agents for Fluorescence-Guided Glioblastoma Surgery - PMC - PubMed Central, accessed June 19, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC12115318/
3. Comparative Analysis of Clinical Outcomes in High-Grade Glioma Patients: 5-ALA Fluorescence-Guided Surgery vs. Conventional White-Light Resection - MDPI, accessed June 19, 2025, https://www.mdpi.com/2072-6694/17/12/1897
4. The Clinical Application of Fluorescence-Guided Surgery in Head and Neck Cancer - PMC, accessed June 19, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6581234/
5. SarcoSIGHT- A randomised controlled trial of fluorescence guided sarcoma surgery versus standard of care - NIHR Funding and Awards, accessed June 19, 2025, https://fundingawards.nihr.ac.uk/award/NIHR134276
6. Definition of tozuleristide - NCI Drug Dictionary, accessed June 19, 2025, https://www.cancer.gov/publications/dictionaries/cancer-drug/def/tozuleristide
7. What is Tozuleristide used for? - Patsnap Synapse, accessed June 19, 2025, https://synapse.patsnap.com/article/what-is-tozuleristide-used-for
8. A first-in-human study of BLZ-100 (tozuleristide) demonstrates ..., accessed June 19, 2025, https://pubmed.ncbi.nlm.nih.gov/34401600/
9. Blaze Bioscience Announces Enrollment is Complete on its Pivotal Phase 2/3 Trial of tozuleristide and the CanvasTM Imaging System in Pediatric Central Nervous System Tumors, accessed June 19, 2025, https://www.businesswire.com/news/home/20221102005383/en/Blaze-Bioscience-Announces-Enrollment-is-Complete-on-its-Pivotal-Phase-23-Trial-of-tozuleristide-and-the-CanvasTM-Imaging-System-in-Pediatric-Central-Nervous-System-Tumors
10. A first-in-human study of BLZ-100 (tozuleristide) demonstrates tolerability and safety in skin cancer patients - 1Search@OSU, accessed June 19, 2025, https://search.library.oregonstate.edu/discovery/fulldisplay?docid=cdi_unpaywall_primary_10_1016_j_conctc_2021_100830&context=PC&vid=01ALLIANCE_OSU:OSU&lang=en&search_scope=OSU_Everything_Profile&adaptor=Primo%20Central&tab=Everything&query=sub%2Cequals%2C%20Cystine-Knot%20Miniproteins%20&offset=0
11. Blaze Bioscience Announces the Publication of Phase 1 Clinical Trial Results for Tumor Paint: BLZ-100 (tozuleristide) in Adults with Glioma - BioSpace, accessed June 19, 2025, https://www.biospace.com/blaze-bioscience-announces-the-publication-of-phase-1-clinical-trial-results-for-tumor-paint-blz-100-tozuleristide-in-adults-with-glioma
12. Blaze Bioscience Announces the Initiation of Pivotal Clinical Trial for Tumor Paint: BLZ-100 (tozuleristide) and the Canvas Imaging System - BioSpace, accessed June 19, 2025, https://www.biospace.com/blaze-bioscience-announces-the-initiation-of-pivotal-clinical-trial-for-tumor-paint-blz-100-tozuleristide-and-the-canvas-imaging-system
13. Blaze Bioscience, accessed June 19, 2025, https://www.blazebioscience.com/
14. Blaze Bioscience Announces FDA Has Granted Fast Track Designation to BLZ-100 (tozuleristide) for Pediatric Central Nervous System Tumors - BioSpace, accessed June 19, 2025, https://www.biospace.com/blaze-bioscience-announces-fda-has-granted-fast-track-designation-to-blz-100-tozuleristide-for-pediatric-central-nervous-system-tumors
15. Tozuleristide - Drug Targets, Indications, Patents - Patsnap Synapse, accessed June 19, 2025, https://synapse-patsnap-com.libproxy1.nus.edu.sg/drug/5c73919fc6e64d66b6ced1821bd54ddd
16. Blaze Bioscience, Inc. - Drug pipelines, Patents, Clinical trials - Patsnap Synapse, accessed June 19, 2025, https://synapse.patsnap.com/organization/e11b68b818720510d07a7b616e70f07d
17. (PDF) A phase II/III randomized, blinded study of tozuleristide for fluorescence imaging detection during neurosurgical resection of pediatric primary central nervous system (CNS) tumors: PNOC012 (Pacific Pediatric Neuro-oncology Consortium). - ResearchGate, accessed June 19, 2025, https://www.researchgate.net/publication/341637863_A_phase_IIIII_randomized_blinded_study_of_tozuleristide_for_fluorescence_imaging_detection_during_neurosurgical_resection_of_pediatric_primary_central_nervous_system_CNS_tumors_PNOC012_Pacific_Pediatr
18. Chlorotoxin binds to both matrix metalloproteinase 2 and neuropilin 1 - PMC, accessed June 19, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10477481/
19. A first-in-human study of BLZ-100 (tozuleristide) demonstrates tolerability and safety in skin cancer patients - ResearchGate, accessed June 19, 2025, https://www.researchgate.net/publication/353712251_A_first-in-human_study_of_BLZ-100_tozuleristide_demonstrates_tolerability_and_safety_in_skin_cancer_patients
20. Fluorescence-Guided Surgery: A Review on Timing and Use in Brain Tumor Surgery - Frontiers, accessed June 19, 2025, https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2021.682151/full
21. Precision Surgery Guided by Intraoperative Molecular Imaging | Journal of Nuclear Medicine, accessed June 19, 2025, https://jnm.snmjournals.org/content/63/11/1620
22. Precision Surgery Guided by Intraoperative Molecular Imaging - PMC - PubMed Central, accessed June 19, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC9635678/
23. Diagnostic and Therapeutic Approaches for Glioblastoma and Neuroblastoma Cancers Using Chlorotoxin Nanoparticles - MDPI, accessed June 19, 2025, https://www.mdpi.com/2072-6694/15/13/3388
24. Neuropilin-1 drives tumor-specific uptake of chlorotoxin - PMC, accessed June 19, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6580635/
25. Structural basis for the binding of the cancer targeting scorpion toxin, ClTx, to the vascular endothelia growth factor receptor neuropilin-1 - ResearchGate, accessed June 19, 2025, https://www.researchgate.net/publication/353647782_Structural_basis_for_the_binding_of_the_cancer_targeting_scorpion_toxin_ClTx_to_the_vascular_endothelia_growth_factor_receptor_neuropilin-1
26. Chlorotoxin binds to both matrix metalloproteinase 2 and neuropilin 1 - ResearchGate, accessed June 19, 2025, https://www.researchgate.net/publication/372029485_Chlorotoxin_binds_to_both_matrix_metalloproteinase_2_and_neuropilin_1
27. Pramod Butte's research works | Cedars-Sinai Medical Center and other places, accessed June 19, 2025, https://www.researchgate.net/scientific-contributions/Pramod-Butte-38656602
28. Phase 1 Safety, Pharmacokinetics, and Fluorescence Imaging Study of Tozuleristide (BLZ-100) in Adults With Newly Diagnosed or Recurrent Gliomas - PubMed, accessed June 19, 2025, https://pubmed.ncbi.nlm.nih.gov/31069381/
29. Safety Study of BLZ-100 in Adult Subjects With Glioma Undergoing Surgery - LarvolClin, accessed June 19, 2025, https://clin.larvol.com/trial-detail/NCT02234297
30. Toxins, Biological | DrugBank Online, accessed June 19, 2025, https://go.drugbank.com/categories/DBCAT000185
31. PNOC012: Study of Tozuleristide and the Canvas Imaging System in ..., accessed June 19, 2025, https://pnoc.us/clinical-trial/pnoc012/
32. A first-in-human study of BLZ-100 (tozuleristide) demonstrates tolerability and safety in skin cancer patients - PubMed Central, accessed June 19, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC8355837/
33. Tozuleristide pharmacokinetics from phase 1 studies in adult and pediatric subjects with central nervous system tumors undergoing surgery. - ASCO Publications, accessed June 19, 2025, https://ascopubs.org/doi/10.1200/JCO.2018.36.15_suppl.e14562
34. INDIGO: A global, randomized, double-blind, phase III study of vorasidenib (VOR; AG-881) vs placebo in patients (pts) with residual or recurrent grade II glioma with an isocitrate dehydrogenase 1/2 (IDH1/2) mutation. | Journal of Clinical Oncology - ASCO Publications, accessed June 19, 2025, https://ascopubs.org/doi/10.1200/JCO.2020.38.15_suppl.TPS2574
35. A phase II/III randomized, blinded study of tozuleristide for fluorescence imaging detection during neurosurgical resection of pediatric primary central nervous system (CNS) tumors - ASCO Publications, accessed June 19, 2025, https://ascopubs.org/doi/10.1200/JCO.2020.38.15_suppl.TPS2575
36. Press Releases - Blaze Bioscience, accessed June 19, 2025, https://www.blazebioscience.com/press-releases
37. Fluorescence Image-Guided Surgery – a Perspective on Contrast Agent Development - PMC - PubMed Central, accessed June 19, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC7115043/
38. Publications - Blaze Bioscience, accessed June 19, 2025, https://www.blazebioscience.com/publications
39. Blaze Bioscience Announces FDA Has Granted Fast Track Designation to BLZ-100 (tozuleristide) for Pediatric Central Nervous System Tumors - Business Wire, accessed June 19, 2025, https://www.businesswire.com/news/home/20200407005238/en/Blaze-Bioscience-Announces-FDA-Has-Granted-Fast-Track-Designation-to-BLZ-100-tozuleristide-for-Pediatric-Central-Nervous-System-Tumors
40. Fluorescence-Guided Surgical Techniques in Adult Diffuse Low-Grade Gliomas - PubMed Central, accessed June 19, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11311317/
41. Fluorescence Guidance in Glioma Surgery: A Narrative Review of Current Evidence and the Drive Towards Objective Margin Differentiation - MDPI, accessed June 19, 2025, https://www.mdpi.com/2072-6694/17/12/2019
42. 5-Aminolevulinic acid (5-ALA) in paediatric brain tumour surgery-a systematic review and exploration of fluorophore alternatives - PubMed, accessed June 19, 2025, https://pubmed.ncbi.nlm.nih.gov/40178625/?utm_source=FeedFetcher&utm_medium=rss&utm_campaign=None&utm_content=1hwQrn1DrkW0IYY-TwhK_LY_mvFnh6IJgOvHT5n5q3-hOpjgyk&fc=None&ff=20250404093703&v=2.18.0.post9+e462414
43. (PDF) How Reliable Is Fluorescence-Guided Surgery in Low-Grade ..., accessed June 19, 2025, https://www.researchgate.net/publication/373176971_How_Reliable_Is_Fluorescence-Guided_Surgery_in_Low-Grade_Gliomas_A_Systematic_Review_Concerning_Different_Fluorophores
44. The Neurosurgeon's Armamentarium for Gliomas: An Update on Intraoperative Technologies to Improve Extent of Resection - MDPI, accessed June 19, 2025, https://www.mdpi.com/2077-0383/10/2/236
45. TOZULERISTIDE - GSRS, accessed June 19, 2025, https://gsrs.ncats.nih.gov/ginas/app/beta/substances/835UH424TU
46. TOZULERISTIDE - Inxight Drugs - ncats, accessed June 19, 2025, https://drugs.ncats.io/drug/835UH424TU
47. Press Releases - Archive - Blaze Bioscience, accessed June 19, 2025, https://www.blazebioscience.com/press-releases-archive
48. Blaze Bioscience gets Fast Track approval from FDA for 'Tumor Paint' that helps remove brain tumors - GeekWire, accessed June 19, 2025, https://www.geekwire.com/2020/blaze-bioscience-gets-fast-track-approval-fda-tumor-paint-helps-remove-brain-tumors/
49. tozuleristide - FirstWord Pharma, accessed June 19, 2025, https://firstwordpharma.com/river/tag/fw_product/tozuleristide
50. Blaze Bioscience Inc. Re: Submission of Clinical Trial Results ... - FDA, accessed June 19, 2025, https://www.fda.gov/media/177625/download
51. How Reliable Is Fluorescence-Guided Surgery in Low-Grade Gliomas? A Systematic Review Concerning Different Fluorophores - PubMed Central, accessed June 19, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10452554/
52. Tozuleristide - Blaze Bioscience - AdisInsight - Springer, accessed June 19, 2025, https://adisinsight.springer.com/drugs/800039924
53. Agents for Fluorescence-Guided Glioblastoma Surgery - MDPI, accessed June 19, 2025, https://www.mdpi.com/1999-4923/17/5/637
54. Venom-derived peptides for breaking through the glass ceiling of drug development, accessed June 19, 2025, https://www.researchgate.net/publication/384772605_Venom-derived_peptides_for_breaking_through_the_glass_ceiling_of_drug_development
55. Venom-derived peptides for breaking through the glass ceiling of drug development - PMC, accessed June 19, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11468230/
56. CORRECTING and REPLACING Blaze Bioscience Announces the Initiation of Pivotal Clinical Trial for Tumor Paint: BLZ-100 (tozuleristide) and the Canvas Imaging System - BioSpace, accessed June 19, 2025, https://www.biospace.com/correcting-and-replacing-blaze-bioscience-announces-the-initiation-of-pivotal-clinical-trial-for-tumor-paint-blz-100-tozuleristide-and-the-canvas-imaging-system
57. PEPN2415: AZD1390 for High-Grade Gliomas | St. Jude Care & Treatment, accessed June 19, 2025, https://www.stjude.org/care-treatment/clinical-trials/pepn2415-high-grade-gliomas.html
58. Fluorescence Detection of Adult Primary Central Nervous System Tumors with Tozuleristide and the Canvas System - National Brain Tumor Society, accessed June 19, 2025, https://trials.braintumor.org/trials/NCT04743310
59. FDA Grants Orphan Drug Designation to OPN-6602 for R/R Multiple Myeloma - OncLive, accessed June 19, 2025, https://www.onclive.com/view/fda-grants-orphan-drug-designation-to-opn-6602-for-r-r-multiple-myeloma
60. FDA Pipeline Priority Reviews for Immunotherapy Based on Biomarker Status, Combination First-Line Therapy in Lung Cancer - The ASCO Post, accessed June 19, 2025, https://ascopost.com/news/april-2020/fda-pipeline-priority-reviews-for-immunotherapy-based-on-biomarker-status-combination-first-line-therapy-in-lung-cancer/
61. EU/3/20/2357 - orphan designation for treatment of oesophageal cancer | European Medicines Agency (EMA), accessed June 19, 2025, https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2357
62. Orphan designation: Overview | European Medicines Agency (EMA), accessed June 19, 2025, https://www.ema.europa.eu/en/human-regulatory-overview/orphan-designation-overview
63. State of the Art: Precision Surgery Guided by Intraoperative Molecular Imaging - Journal of Nuclear Medicine, accessed June 19, 2025, https://jnm.snmjournals.org/content/jnumed/early/2022/08/11/jnumed.121.263409.full.pdf
64. Fluorescence-Guided Surgery | University of Pittsburgh, accessed June 19, 2025, https://www.neurosurgery.pitt.edu/centers/image-guided-neurosurgery/fgs
65. RAS70 peptide targets multiforme glioblastoma by binding to the plasma membrane heat shock protein HSP70 - Frontiers, accessed June 19, 2025, https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2025.1543657/full
66. BLZ-100 (Tozuleristide, Tumor Paint™). Schematic* of the peptide CTX (targeting motif, accessed June 19, 2025, https://www.researchgate.net/figure/BLZ-100-Tozuleristide-Tumor-Paint-Schematic-of-the-peptide-CTX-targeting-motif_fig2_352865025
67. Molecular-Guided Surgery: Molecules, Devices, and Applications XI - SPIE, accessed June 19, 2025, https://spie.org/pwb/conferencedetails/molecular-guided-surgery
68. Fluorescence guided surgery imaging systems for breast cancer identification: a systematic review - SPIE Digital Library, accessed June 19, 2025, https://www.spiedigitallibrary.org/journals/journal-of-biomedical-optics/volume-29/issue-03/030901/Fluorescence-guided-surgery-imaging-systems-for-breast-cancer-identification/10.1117/1.JBO.29.3.030901.full
69. Tozuleristide: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed June 19, 2025, https://go.drugbank.com/drugs/DB15375
70. central nervous system tumors - Amazon S3, accessed June 19, 2025, https://s3.amazonaws.com/files.oncologymeetings.org/prod/s3fs-public/2020-05/AM20-CENTRAL-NERVOUS-SYSTEM-TUMORS.pdf?null
71. Optical Imaging Technology for In Vivo Tumor Detection | Request PDF - ResearchGate, accessed June 19, 2025, https://www.researchgate.net/publication/392663597_Optical_Imaging_Technology_for_In_Vivo_Tumor_Detection
72. Clinical Trials - Pediatric Neuro-Oncology Consortium, accessed June 19, 2025, https://pnoc.us/clinical-trials/
73. Blaze Bioscience Announces Enrollment is Complete on its Pivotal Phase 2/3 Trial of tozuleristide and the CanvasTM Imaging System in Pediatric Central Nervous System Tumors, accessed June 19, 2025, https://www.neuro-central.com/blaze-bioscience-announces-enrollment-is-complete-on-its-pivotal-phase-2-3-trial-of-tozuleristide-and-the-canvastm-imaging-system-in-pediatric-central-nervous-system-tumors/
74. Fluorescence-Guided Surgery: A Review on Timing and Use in Brain Tumor Surgery - PMC, accessed June 19, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC8245059/
75. (PDF) Phase 1 Safety, Pharmacokinetics, and Fluorescence Imaging Study of Tozuleristide (BLZ-100) in Adults With Newly Diagnosed or Recurrent Gliomas - ResearchGate, accessed June 19, 2025, https://www.researchgate.net/publication/333002193_Phase_1_Safety_Pharmacokinetics_and_Fluorescence_Imaging_Study_of_Tozuleristide_BLZ-100_in_Adults_With_Newly_Diagnosed_or_Recurrent_Gliomas
76. Fluorescence imaging-guided surgery: current status and future directions - RSC Publishing, accessed June 19, 2025, https://pubs.rsc.org/en/content/articlehtml/2024/bm/d4bm00410h
77. Purification and characterization of chlorotoxin, a chloride channel ligand from the venom of the scorpion - American Journal of Physiology, accessed June 19, 2025, https://journals.physiology.org/doi/abs/10.1152/ajpcell.1993.264.2.C361
78. Receptor-Targeted Fluorescence-Guided Surgery With Low Molecular Weight Agents - Frontiers, accessed June 19, 2025, https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2021.674083/full
79. Chlorotoxin binds to both matrix metalloproteinase 2 and neuropilin ..., accessed June 19, 2025, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10477481/